NasdaqGS:AMGNBiotechs
Is Amgen (AMGN) Fully Valued On Strong Q2 Results And Raised 2026 Guidance?
Amgen (AMGN) is back in focus after its Q2 2026 report and raised full year guidance, which highlighted stronger earnings expectations and a pipeline that management presents as a key long term driver.
See our latest analysis for Amgen.
Amgen's share price has reacted strongly to the Q2 2026 earnings beat and raised guidance, with a 15.46% 1 month share price return and 27.02% year to date share price return, while the 5 year total shareholder return of 113.11% points to sustained long term...